Company History - The Milestones
2019 (September) The Company began shipping Kush syringes to key opinion leaders in the veterinary community.
2019 (August) PetVivo announces exclusive license agreement with Emerald Organic Products, Inc. for the use of our muco-adhesion technology, a patented oral delivery method for various substances including caffeine and cannabidiol (“CBD”).
2019 (July) The Board appointed Mr. Gregory Cash as the Chairman of the Board, Mr. John Lai as CEO, Mr. John Carruth as CFO, and Mr. John Dolan as Secretary of the Company, solidifying the leadership team.
2019 (June) The Company shareholders elected three new Directors to the Board.
2018 (July) PetVivo moves manufacturing to CytoMedical Design Group (cmdg) in St. Paul, Minnesota.
2018 (June) Company establishes first production. Starts to build sales distribution for soft roll out of the Kush™ System. First target markets include Minnesota, Colorado, Arizona, Texas and Florida.
2018 (June) Two new patents are issued with the assistance of the Company’s new patent lawyer, Craige Thompson of Thompson Patent Law in Austin, Texas.
2018 (April) Mr. John Carruth accepts the position of Controller.
2018 (January-July) Advisory Board is reorganized to include Tracy Turner DVM, MS, Brad Gordon DVM, Michael Sterns, Michael Haider, John Wagoner, Robin Young and Thomas Yezzi.
2017 (November) The Company leases a new company headquarters and manufacturing facility in Edina, a suburb of Minneapolis, Minnesota. The new location expands the company’s production and office space requirements for veterinary product commercialization.
2017 (August) Three new members added to the Board of Directors: David Deming, Peter Vezmar and David Merrill.
2017 (August) Completes capital raise to set up manufacturing facility and bring on Randy Wenthold, Chief Science Officer.
2017 (June) Dr. Masters is invited to speak on the effectiveness of our particles as an osteoarthritis treatment at the Society for Biomaterials Annual Meeting. The presentation is titled “Particles for Osteoarthritis Treatment: Injected Wet Particulate of Collagen-Elastin-Glycosaminoglycan Matrix into Synovial Fluid Mechanically Cushion Joint with Long Duration.” To recognize significant advances in the field, Dr. Masters is awarded the Star Award for his abstract with the same title.
2017 (April) Gel-Del Technologies, Inc. & PetVivo Holdings, Inc. complete the merger of the two entities. Gel-Del remains as a wholly-owned subsidiary of PetVivo.